Rigel Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
/ 
Frequently asked questions
To buy Rigel Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Rigel Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Rigel Pharmaceuticals Inc. is RIGL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Rigel Pharmaceuticals Inc. has its primary listing on NASDAQ. You can trade Rigel Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Rigel Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Rigel Pharmaceuticals Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Rigel Pharmaceuticals Inc..